SHUKRAPHAR · NSE
Shukra Pharmaceuticals Limited
₹55.93
+3.12% (+₹1.69)
Prev. close
₹54.24
Volume
34,23,614
Delivery %
35.4%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited engages in the manufacturing, marketing, and export of pharmaceutical formulations in India and internationally. The company offers various products, such as antibiotics, anti biotics, macrolides, quinolones, anti bacterial, anti fungal, anti malarial, anti viral, anti protozoal, anti anthelmintic, sedative and tranquilliser, anti depressant, anti manic, anti emetic, anti ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti tuberculosis, vitamin products, anti allergics, corticosteroids, hyper and hypoglycemic, and other products. It provides its products in ampoules, capsules, vials, and tablet forms. In addition, the company provides laboratory services; and surgical robots, diabetes technologies, cardiac sciences, advanced surgical and diagnostic solutions, imaging and critical care, medical simulations, wound care, boron neutron capture therapy, and virtual autopsy and forensic sciences. Further, it is involved in the supplying, selling, and distributing medical consumables; offers wound care products, medical, surgical, healthcare devices, materials, consumables, and allied solutions, as well as diabetes-related medical technologies solutions; and provision of virtual autopsy services and solutions. Additionally, the company offers expendable and non-expendable medical products, medical devices, emergency healthcare systems, combat medical support systems, first aid kits, trauma care kits; and artificial intelligence (AI), machine learning, deep learning, data analytics, predictive analytics, computer vision, natural language processing, generative AI, robotics, automation, digital platforms, hardware, cloud-based systems, decision support systems, and other technology solutions. The company was formerly known as Relish Pharmaceuticals Limited and changed its name to Shukra Pharmaceuticals Limited in August 2016. Shukra Pharmaceuticals Limited was incorporated in 1993 and is headquartered in Ahmedabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Dakshesh Rameshchandra Shah
Headquarters
Ahmedabad
Website
shukrapharmaceuticals.comExchange
View on NSE ↗Key stats
Market cap
₹2,465.32 Cr
P/E ratio (TTM)
71.7
Dividend yield
0.02%
EPS (TTM)
₹0.78
Beta (5Y monthly)
0.57
Shares float
4.76 Cr
EPS · quarter ended Jun 2026
₹0.30
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
Other assets floored at zero for years where fixed and current assets exceeded reported total assets.
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹11.20 Cr | ₹20.49 Cr | ₹58.83 Cr | ₹74.57 Cr | ₹32.59 Cr | ₹56.73 Cr | |
| EBITDA | ₹1.80 Cr | ₹2.97 Cr | ₹6.53 Cr | ₹22.21 Cr | ₹16.94 Cr | ₹33.32 Cr |
| ₹3.40 L | ₹75.10 L | ₹4.41 Cr | ₹18.54 Cr | ₹9.58 Cr | ₹22.06 Cr | |
| Diluted EPS | — | — | ₹0.14 | ₹0.42 | ₹0.22 | ₹0.5 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹74.97 Cr | ₹77.84 Cr | ₹86.77 Cr | ₹117.44 Cr | |
| — | — | ₹5.08 Cr | ₹3.15 Cr | ₹4.18 Cr | ₹5.02 Cr | |
| Stockholders' equity | — | — | ₹25.30 Cr | ₹57.63 Cr | ₹62.84 Cr | ₹89.85 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹3.17 Cr | ₹-5.20 Cr | ₹7.92 Cr | ₹3.93 Cr | |
| Investing cash flow | — | — | ₹-4.43 Cr | ₹-1.20 Cr | ₹-1.26 Cr | ₹-14.14 Cr |
| — | — | ₹4.94 Cr | ₹12.41 Cr | ₹-4.52 Cr | ₹4.07 Cr | |
| Capital expenditure | — | — | ₹-4.49 Cr | ₹-1.76 Cr | ₹-2.74 Cr | ₹-15.73 Cr |
| End cash position | — | — | ₹3.97 Cr | ₹9.98 Cr | ₹12.12 Cr | ₹5.98 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Shukra Pharmaceuticals Limited | ₹2,432.71 Cr | ₹55.93 | 70.8 | 27.08 | 24.6% | 0.06 | +74.1% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 23
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.